Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible. The more familiar terms ‘chronic bronchitis’ and ’emphysema’ are no longer used, but are now included within the COPD diagnosis. COPD is not simply a “smoker’s cough” but an under-diagnosed, life-threatening lung disease. According to the World Health Organization.
From the Journal of STEM CELLS
Current Status of Stem Cells and Regenerative Medicine in Lung Biology and Diseases
Lung diseases remain a significant and devastating cause of morbidity and mortality worldwide. In contrast to many other major diseases, lung diseases notably chronic obstructive pulmonary diseases (COPDs), including both asthma and emphysema, are increasing in prevalence and COPD is expected to become the third leading cause of disease mortality worldwide by 2020.
New therapeutic options are desperately needed. A rapidly growing number of investigations of stem cells and cell therapies in lung biology and diseases have offered exciting new avenues for advancing knowledge of lung biology as well as providing potential therapeutic approaches for lung diseases.
MSCs and Immunomodulation of Lung Diseases
MSCs are being widely investigated for their immunomodulatory effects in a wide range of inflammatory and immune diseases. MSCs can influence behavior of both surrounding structural cells and also surrounding inflammatory cells.
As such a rapidly growing number of studies demonstrate efficacy of MSC administration in a growing spectrum of lung diseases. This includes over 90 publications to date in models of acute lung injury and bacterial lung infection, asthma, bronchiolitis obliterans, BPD, COPD, fibrosing pulmonary injury, pulmonary hypertension, pulmonary ischemia reperfusion injury, obstructive sleep apnea, radiation-induced lung injury, sepsis and burns, and other critical illness or autoimmune-related lung injuries including hemorrhagic shock, pancreatitis, silicosis, and ventilator-induced lung injury. Administration of MSCs has also been demonstrated to decrease injury and inflammation in endotoxin or bacterially injured human lung explants.
A growing number of studies demonstrates efficacy of human MSCs in lung injury models in both immune-deficient as well as immune-competent.
What can be done to help COPD?
At Total Health Institute we have addressed the primary method to wake up your sleeping or dormant Stem Cells for the last 35 years. This is done through addressing the 10 causes of inflammation. Now a whole new level of awakening your own stem cells and promoting regeneration, decreasing inflammation and pathogens at the highest level can be achieved. We call this Total Health Stem Cell.